Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.

摘要: Curative therapies for clinically localized prostate cancer have significant morbidity, and those patients who might be cured by aggressive management are not easily identified using current clinical information. Better biomarkers of tumor behavior need to improve outcome. Chondroitin sulfate (CS), a glycosaminoglycan, may potentially useful biomarker as it is known influence cell growth differentiation malignant progression. In this study, CS was immuno-localized the periacinar peritumoral fibromuscular stromal tissue nonmalignant prostates. The concentration increased in men with early-stage compared from without (P < 0.0001). Using Cox's univariate analysis, concentration, grade, preoperative serum prostate-specific antigen (PSA), extracapsular extension disease, positive surgical margins, patient age were associated an risk PSA failure. other features two-variable regression analyses. concentrations independent predictors stronger prognostic feature than grade could predict outcome moderately differentiated tumors. Patients low had significantly better progression-free survival following radical prostatectomy high levels (Kaplan-Meier plot, 91% versus 49% progression free at 5 years, respectively, P = 0.0038). Only postoperative pathological indices (extracapsular extension, margins) CS. We conclude that measurement prostatic diagnosis allow stratification adjunctive or alternate therapies.